An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311
Status:
Terminated
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
To evaluate the long-term safety, tolerability and potential efficacy, patients who
previously participated in V203-AD study (NCT02551809) will be eligible to participate in the
extension study and will receive 3 or 5 doses of UB-311 within a 96-week treatment period
followed by a 12-week follow-up period.